Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Visa and Mastercard are expected to report higher quarterly profits this week on steady consumer spending, and analysts will ...

"Visa and Mastercard remain top ideas, particularly in an uncertain macro environment, given their broad-based exposure to ...